Mr. Brent Zettl reports

ZYUS LIFE SCIENCES REPORTS PRELIMINARY RESULTS FROM ONGOING PHASE 2A UTOPIA-1 TRIAL EVALUATING NOVEL NON-OPIOID PAIN DRUG

Zyus Life Sciences Corp. has released favourable preliminary results from its continuing phase 2a Utopia-1 (unique treatment of oncology pain in advanced cancer) trial evaluating trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain.

Preliminary results highlights

Utopia-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

Preliminary results from the phase 2a are based on the data from the first 25 per cent of enrolled patients who have completed treatment in the Utopia-1 trial. Early data suggest:

• Reduction in average daily pain, pain interference and pain severity;
• Reduction in opioid dosing for breakthrough pain;
• No serious adverse events related to trichomylin softgel capsules;
• Trichomylin softgel capsules were generally well tolerated, with the majority of adverse reactions being expected, mild and occurring during dose titration, consistent with the company's phase 1 Z-TRI-10001 trial (NCT04867057).

"This is an important milestone as it allows us to assess early outcomes from the first cohort of five patients who have completed treatment and further validates our clinical trial design in this challenging patient population," said Dr. Julie Stakiw, chief medical officer of Zyus. "These results provide initial insight into the safety and preliminary analgesic efficacy of trichomylin softgel capsules as the Utopia-1 trial continues to generate the data needed to support the possible progression into later-stage trials."

"These positive preliminary findings reflect the culmination of more than seven years of scientific rigour and disciplined clinical development," said Brent Zettl, chief executive officer of Zyus. While the data remains early, the signals we are seeing reinforce our belief that trichomylin softgel capsules have the potential to address cancer-related pain through a non-opioid alternative and support our continued efforts to generate robust clinical evidence."

About Zyus Life Sciences Corp.

Zyus is a life science company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, Zyus aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. Zyus's unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions in pursuit of transformational impact on patients' lives.

We seek Safe Harbor.